MedTrace Logo

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

NCT03804580 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-05-07

No results posted yet for this study

Summary

Phase II, single-arm study to assess the safety and efficacy of osimertinib (80 mg, orally, once daily) as first-line therapy in patients with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously treated with an epidermal growth factor tyrosine kinase inhibitor agent.

Conditions

Interventions

DRUG

osimertinib

Non-randomized trial, all patients receive therapy

Sponsors & Collaborators

  • Vestre Viken Hospital Trust

    lead OTHER

Principal Investigators

  • Odd Terje Brustugun, MD PhD · Drammen Hospital - Vestre Viken

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2025-06-01
Completion
2025-12-31

Countries

  • Denmark
  • Lithuania
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804580 on ClinicalTrials.gov